Literature DB >> 8665777

Antiproteinuric effect predicts renal protection by angiotensin-converting enzyme inhibition in rats with established adriamycin nephrosis.

F H Wapstra1, H Van Goor, G Navis, P E De Jong, D De Zeeuw.   

Abstract

1. The mechanism of renal protection by angiotensin-converting enzyme inhibition is still the subject of debate. Inhibition of proteinuria might play a role. If so, a good antiproteinuric response to angiotensin-converting enzyme inhibition should predict subsequent protection against renal structural damage. This hypothesis has not been tested in models where treatment is started after the renal disease is well established, i.e. models that mimic the clinical situation. 2. We therefore investigated this hypothesis in 96 male Wistar rats with established adriamycin nephrosis. Reduction of proteinuria was achieved by lisinopril (0, 2, 5 and 10 mg day-1 kg-1) on two different sodium diets (0.3% and 0.05% NaCl). Therapy started 6 weeks after adriamycin (at stable proteinuria) and was continued for 6 weeks. 3. Lisinopril reduced blood pressure by 32 +/- 4% and proteinuria by an average of 72 +/- 7%, with stabilization after 2 weeks. Considerable interindividual differences in antiproteinuric response was found. Glomerulosclerosis score was reduced by 15 +/- 5%. All the effects of angiotensin-converting enzyme inhibitors were enhanced by sodium depletion, but sodium depletion in itself did not affect blood pressure (124 +/- 4 mmHg), proteinuria (664 +/- 68 mg/day) or glomerulosclerosis score (30 +/- 5%). Interestingly, the more proteinuria was reduced initially in an individual rat, the less sclerosis was found in the long term in that rat. 4. In conclusion, angiotensin-converting enzyme inhibition lowers proteinuria and prevents glomerulosclerosis in established adriamycin nephrosis. These effects are enhanced by sodium depletion. The individual short-term antiproteinuric effect predicts the protection against ultimate glomerular damage. This is consistent with the hypothesis that reduction of proteinuria is a mechanism by which angiotensin-converting enzyme inhibitors exert renoprotection.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8665777     DOI: 10.1042/cs0900393

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  9 in total

Review 1.  Improving the efficacy of RAAS blockade in patients with chronic kidney disease.

Authors:  Hiddo J Lambers Heerspink; Martin H de Borst; Stephan J L Bakker; Gerjan J Navis
Journal:  Nat Rev Nephrol       Date:  2012-12-18       Impact factor: 28.314

Review 2.  ACE inhibitors and the kidney. A risk-benefit assessment.

Authors:  G Navis; H J Faber; D de Zeeuw; P E de Jong
Journal:  Drug Saf       Date:  1996-09       Impact factor: 5.606

3.  Sodium intake, ACE inhibition, and progression to ESRD.

Authors:  Stefan Vegter; Annalisa Perna; Maarten J Postma; Gerjan Navis; Giuseppe Remuzzi; Piero Ruggenenti
Journal:  J Am Soc Nephrol       Date:  2011-12-01       Impact factor: 10.121

4.  Salt-deficient diet exacerbates cystogenesis in ARPKD via epithelial sodium channel (ENaC).

Authors:  Daria V Ilatovskaya; Vladislav Levchenko; Tengis S Pavlov; Elena Isaeva; Christine A Klemens; Jessica Johnson; Pengyuan Liu; Alison J Kriegel; Alexander Staruschenko
Journal:  EBioMedicine       Date:  2019-02-08       Impact factor: 11.205

5.  Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan.

Authors:  Liffert Vogt; Femke Waanders; Frans Boomsma; Dick de Zeeuw; Gerjan Navis
Journal:  J Am Soc Nephrol       Date:  2008-02-13       Impact factor: 10.121

6.  Treatment With Lisinopril Prevents the Early Progression of Glomerular Injury in Obese Dahl Salt-Sensitive Rats Independent of Lowering Arterial Pressure.

Authors:  Andrea K Brown; Alyssa Nichols; Chantell A Coley; Ubong S Ekperikpe; Kasi C McPherson; Corbin A Shields; Bibek Poudel; Denise C Cornelius; Jan M Williams
Journal:  Front Physiol       Date:  2021-12-17       Impact factor: 4.566

7.  Combined sodium glucose co-transporter-2 inhibitor and angiotensin-converting enzyme inhibition upregulates the renin-angiotensin system in chronic kidney disease with type 2 diabetes: Results of a randomized, double-blind, placebo-controlled exploratory trial.

Authors:  Marlies Antlanger; Oliver Domenig; Christopher C Kaltenecker; Johannes J Kovarik; Vincent Rathkolb; Martin M Müller; Elisabeth Schwaiger; Manfred Hecking; Marko Poglitsch; Marcus D Säemann; Chantal Kopecky
Journal:  Diabetes Obes Metab       Date:  2022-01-24       Impact factor: 6.408

Review 8.  Dietary sodium restriction: a neglected therapeutic opportunity in chronic kidney disease.

Authors:  Jelmer K Humalda; Gerjan Navis
Journal:  Curr Opin Nephrol Hypertens       Date:  2014-11       Impact factor: 2.894

9.  Effect of losartan and spironolactone on triglyceride-rich lipoproteins in diabetic nephropathy.

Authors:  Anand Srivastava; Beverley Adams-Huet; Gloria L Vega; Robert D Toto
Journal:  J Investig Med       Date:  2016-07-07       Impact factor: 2.895

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.